

Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma

Citation: Pennell NN, Bhanji T, Zhang L, Seth A, Sawka CA, and Berinstein NL. Lack of prognostic value of FCGR3A-V158F polymorphism in non-Hodgkin's lymphoma. *Haematologica* 2008; doi: 10.3324/haematol.12638

Online Supplementary Table S1. Clinical features according to FCGR3A-V158F.

Variable	Indolent (N=69)			p value	Aggressive (N=125)			p value
	VV	VF	FF		VV	VF	FF	
N. of pts	9 (13)	30 (43)	30 (43)		16 (13)	59 (47)	50 (40)	
Median Age	54	58	57	0.7644	59	62	63	0.8276
Age > 60 yrs	4 (44)	11 (36)	7 (23)	0.3540	7 (44)	34 (58)	26 (52)	0.5960
Stage (III,IV)	5 (56)	24 (80)	22 (73)	0.3515	13 (81)	29 (49)	32 (64)	0.0510
Extra nodal	4(44)	18 (60)	21 (70)	0.3338	10 (63)	32 (54)	30 (60)	0.7701
ECOG PS ≥2	0(0)	2 (7)	1 (3)	0.6469	2 (13)	7 (12)	7 (14)	0.9321
Elevated LDH	0(0)	4 (13)	5 (17)	0.5556	4 (25)	19 (32)	17 (34)	0.8338
IPI score								
0-1	5 (55)	9 (30)	8 (27)		6 (37.5)	18 (30.5)	15 (30)	
2	2 (22)	11 (36)	12 (40)	0.7347	3 (18.8)	20 (33.9)	11 (22)	0.3077
3-5	2 (22)	10 (33)	10 (33)	0.8773	3 (18.8)	21 (35.6)	24 (48)	0.4238
B-symptoms	0 (0)	4 (13)	6 (20)	0.4039	6 (38)	11 (19)	8 (16)	0.1867
Bulk >5 cm	1 (11)	12 (40)	20 (67)	0.0086	7 (44)	35 (59)	32 (64)	0.3698

Number of patients, (%), p values were calculated using Kruskal-Wallis non-parametric test, or Fisher exact test.